139 related articles for article (PubMed ID: 10049285)
1. Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess.
Fernandez J; Barrett JF; Licata L; Amaratunga D; Frosco M
Antimicrob Agents Chemother; 1999 Mar; 43(3):667-71. PubMed ID: 10049285
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Scaglione F; Mouton JW; Mattina R; Fraschini F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Iyer P
J Antimicrob Chemother; 1995 Jun; 35(6):805-19. PubMed ID: 7559192
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
Onyeji CO; Bui KQ; Owens RC; Nicolau DP; Quintiliani R; Nightingale CH
Int J Antimicrob Agents; 1999 Jul; 12(2):107-14. PubMed ID: 10418754
[TBL] [Abstract][Full Text] [Related]
5. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Dajcs JJ; Thibodeaux BA; Marquart ME; Girgis DO; Traidej M; O'Callaghan RJ
Antimicrob Agents Chemother; 2004 Jun; 48(6):1948-52. PubMed ID: 15155183
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
[TBL] [Abstract][Full Text] [Related]
8. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
[TBL] [Abstract][Full Text] [Related]
9. In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
Yagel SK; Barrett JF; Amaratunga DJ; Frosco MB
Antimicrob Agents Chemother; 1996 Dec; 40(12):2894-7. PubMed ID: 9124863
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.
Frosco MB; Melton JL; Stewart FP; Kulwich BA; Licata L; Barrett JF
Antimicrob Agents Chemother; 1996 Nov; 40(11):2529-34. PubMed ID: 8913458
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci.
Entenza JM; Caldelari I; Glauser MP; Moreillon P
J Antimicrob Chemother; 1999 Dec; 44(6):775-86. PubMed ID: 10590278
[TBL] [Abstract][Full Text] [Related]
12. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification.
Bucci FA
Am J Ophthalmol; 2004 Feb; 137(2):308-12. PubMed ID: 14962422
[TBL] [Abstract][Full Text] [Related]
13. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
Croom KF; Goa KL
Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
[TBL] [Abstract][Full Text] [Related]
14. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.
Nicodemo AC; Robledo JA; Jasovich A; Neto W
Int J Clin Pract; 1998 Mar; 52(2):69-74. PubMed ID: 9624783
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
16. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
Lister PD; Sanders CC
J Antimicrob Chemother; 1999 Jan; 43(1):79-86. PubMed ID: 10381104
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
Madaras-Kelly KJ; Demasters TA
Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
Szabó D; Máthé A; Lengyel J; Anderlik P; Rókusz L; Rozgonyi F
Curr Med Chem; 2002 Feb; 9(4):437-42. PubMed ID: 11945119
[TBL] [Abstract][Full Text] [Related]
20. Efficacies of ofloxacin, rifampin, and clindamycin in treatment of Staphylococcus aureus abscesses and correlation with results of an in vitro assay of intracellular bacterial killing.
Bamberger DM; Herndon BL; Dew M; Chern RP; Mitchell H; Summers LE; Marcus RF; Kim SC; Suvarna PR
Antimicrob Agents Chemother; 1997 May; 41(5):1178-81. PubMed ID: 9145896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
